- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03645057
ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis
October 27, 2022 updated by: Julie Ryan Wolf, University of Rochester
ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS
This is an open-label, randomized, cross-sectional study to monitor the effects of crisaborole and tacrolimus 0.03% on patient-reported outcomes and caregiver burden in children (ages 2 to 15 years, inclusive) with ≤ moderate atopic dermatitis over a 12 week period of time.
The goal of this study is to detect changes in PROs and caregiver burden during treatment for atopic dermatitis of moderate or less severity.
The study design will allow us to correlate PROs and caregiver burden with treatment response and disease improvement in children.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Atopic dermatitis (AD) is a common, chronic skin disease affecting 20% of children and 10% of adults worldwide (1-3).
Children with AD often develop the disease within the first five years of life, which is a critical time for physical and psychosocial development (4).
AD impacts an individual's physical, mental, and social health.
Anxiety, itch, sleep disturbance, and depression have been associated with low quality of life scores.
Childhood AD also affects the emotional, financial, physical, and social well-being of parents or caregivers (4).
Individuals caring for a child with AD report sleep deprivation, poor social support, and stress about parenting (1, 4).
Utilizing patient-reported outcomes (PROs) in clinic can provide meaningful data to monitor disease activity and response to different interventions, with the ultimate goal to improve quality of life for the patient and their family members or caregivers.
Additionally, PROs can help us better understand the burden of AD.
It is still unclear which PROs are most relevant for atopic dermatitis.
This study will evaluate the utility of several PROs to monitor response to two different topical ointments, crisaborole (Eucrisa™) and tacrolimus 0.03%, to better understand the impact of these two non-steroidal topical treatments on overall health of children with AD of moderate or less severity and their caregivers.
Study Type
Interventional
Enrollment (Actual)
92
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester Dermatology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 15 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Pediatric Subjects:
- Male and female subjects of inclusive ages of 2 to 15 years (inclusive) at screening visit.
- Diagnosis of ≤moderate atopic dermatitis or eczema (ISGA 2 or 3 and ≥3% BSA, excluding scalp).
- If subject is taking or prescribed antihistamines, subject must be on stable dose of antihistamines.
- If subject is taking or prescribed topical steroids, subject must be on stable dose of topical steroids.
- If taking a systemic anti-inflammatory medication for atopic dermatitis or other condition, subject must be on stable dose of the systemic anti-inflammatory medication for six weeks prior to enrollment.
- If subject is currently taking or prescribed tacrolimus or crisaborole, or other steroid-sparring medication, subject must agree to two week (i.e., 14 days) washout period prior to randomization and Baseline Assessment for study.
- Caregiver (i.e., adult parent or guardian) must agree to participate in the study with the patient.
e) Subject must be able to read and speak English. f) Subject ages ≥8 years, is able to give assent.
Caregiver Subjects:
- Subject must be at least 18 years old and the parent or guardian of the eligible pediatric subject.
- Subject must be able to read and speak English.
- Subject must be able to give informed consent.
Exclusion Criteria:
- Pediatric subjects <2 years old or >15 years old are not eligible for participation in this study.
- Pediatric subjects with a diagnosis with another skin disease (i.e., not atopic dermatitis or eczema) are excluded to prevent confounding of results.
- Pediatric subjects currently on systemic anti-inflammatory therapy for atopic dermatitis or other indication are excluded.
- Caregiver subject <18 years old are excluded.
- Pediatric subject participation without caregiver participation is not allowed.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Crisaborole
The topical treatment will be applied to all affected areas twice daily for 12 weeks.
|
This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children.
Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
Other Names:
|
Active Comparator: Tacrolimus 0.03%
The topical treatment will be applied to all affected areas twice daily for 12 weeks.
|
This topical ointment is FDA-approved to treat atopic dermatitis in children.
Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Children's PROMIS Pediatric Itch Short-Form
Time Frame: baseline to 12 weeks
|
This is a patient-reported outcome measure for Itch in pediatric patients that consists of 8 fixed items items, spanning four domains (general, activity, mood/sleep, and scratching behavior).
Each item is scored on using 1 = No Itch, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very Severe.
The range of the scale is 1 to 5 with higher numbers indicating worse outcome.
A total score, representing overall itch-related quality of life, is scored by taking the average (i.e., divide by 8) of the sum of all 8 items.
Therefore, total itch scores range between 1 and 5, with higher scores indicating worse impact of itch on quality of life.
The measure was completed electronically on an iPad using REDCap.
|
baseline to 12 weeks
|
Mean Change in PROMIS Pain Interference-Children (Adaptive Test)
Time Frame: baseline to 12 weeks
|
This is a patient reported outcome measure for pain interference in pediatric patients.
This is a computer adaptive test consisting of 4-12 questions related to how pain interferes with daily activities.
The number of questions a patient answers depends on how he or she answers each question.
The overall domain score ranges from 0 to100 with a score of 50 representing the average score for the general population.
Higher scores indicate greater pain interference.
A score above 55 is considered "clinically significant" for each domain.
A score change of 5 or more is considered a clinically important change in domain severity.
This measure was completed electronically on an iPad using REDCap.
|
baseline to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Children's Dermatology Life Quality Index
Time Frame: baseline to 12 weeks
|
This patient-reported outcome measure will be completed using an iPad.
The 10-item questionnaire designed for use in parents of children (i.e., ages 4-17) to obtain information on children's quality of life.
Each question relates to a component of quality of life: Symptoms/Feelings (items 1-2); Leisure (items 4-6); School (item 7); Relationships (items 3-8); Sleep (item 9), and Treatment (item 10).
Children answer each question using a 4-point scale: Not at all = 0, A Little = 1, Quite A Lot = 2, Very Much = 3.
The scores from each item are summed to create a severity burden score (i.e., minimum score = 0; maximum score = 30).
Higher the scores, the greater burden on quality of life.
The scores represent degree of severity burden on quality of life: No effect = 0-1; Small effect = 2-6; Moderate effect = 7-12; Very large effect = 13-18; and Extremely large effect = 19-30.
|
baseline to 12 weeks
|
Mean Change in Children's Sleep Habits Questionnaire
Time Frame: Baseline to 12 Weeks
|
This patient-reported outcome measure was completed by the caregiver using an iPad.
This is a validated 22 item questionnaire consisting of 4 subscales: Bedtime, Sleep Behavior, Waking During the Night, and Morning Wake Up.
The patient/parent will answer each item choosing from: "Always" if something occurs every night; "Usually" if it occurs 5 or 6 times a week; "Sometimes" if it occurs 2 to 4 times a week; "Rarely" if it occurs once a week; and "Never" if it occurs less than once a week.
Each question is scored on a 3-point scale as 1 = Usually and Always (5-7 times/week); 2 = Sometimes" (2-4 times/week); or 3 = Rarely and Never (0-1 time/week).
The scores are combined from each subscale to generate a Total Sleep Disturbance Score, which can range from 22 (minimum) to 66 (maximum).
The higher the score, the greater the sleep disturbance.
A Total Sleep Disturbances score over 28 represent clinically significant sleep disturbance.
|
Baseline to 12 Weeks
|
Mean Change in PROMIS Anxiety-children (Adaptive Test)
Time Frame: baseline to 12 weeks
|
This patient-reported outcome measure will be completed by the child patient electronically on an iPad using computer adaptive test (CAT).
The CAT consists of 4-12 questions on feelings related to anxiety.
The number of questions a patient answers depends on how he or she answers each question.
The domain score is a t-score ranging from 0 to 100 with a score of 50 representing the average score for the general population.
Higher scores indicate greater anxiety.
A score above 55 is considered "clinically significant" for each domain.
A score change of 5 or more is considered a clinically important change in domain severity.
This PRO was completed electronically on an iPad using REDCap.
|
baseline to 12 weeks
|
Mean Change in PROMIS Depressive Symptoms-Pediatric (Adaptive Test)
Time Frame: baseline to 12 weeks
|
This patient-reported outcome measure s will be completed by the child patient electronically on an iPad using computer adaptive test (CAT).
The CAT consists of 4-12 questions on feelings related to depressive symptoms.
The number of questions a patient answers depends on how he or she answers each question.
The domain score is a t-score ranging from 0 to 100 with a score of 50 representing the average score for the general population.
Higher scores indicate greater depressive symptoms.
A score above 55 is considered "clinically significant" for each domain.
A score change of 5 or more is considered a clinically important change in domain severity.
This PRO was completed electronically on an iPad using REDCap.
|
baseline to 12 weeks
|
Mean Change in Children's Eczema Area & Severity Index (EASI)
Time Frame: baseline to 12 weeks
|
Clinician rated the severity of atopic dermatitis using the EASI.
The EASI is a tool used to measure the extent (area) and severity of AD.
It does not include a grade for dryness or scaling and includes only inflamed areas.
The area score is a 7-point scale representing the percentage of skin affected by AD for each body region.
The severity score is recorded for each of the four regions of the body and is the sum of the intensity scores for four signs.
The four signs include redness, thickness, scratching, and lichenification.
The intensity scores are performed using a 4-pont scale.
The final EASI score is the sum of the total scores for each region.
Add up the total scores for each region to determine the final EASI score.
The minimum EASI score is 0 and the maximum EASI score is 72.
Higher scores represent worse AD severity.
|
baseline to 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Caregiver Burden Inventory
Time Frame: baseline to 12 weeks
|
The CBI is a 24-item, five-subscale Caregiver Burden Inventory (CBI) and demonstrates its use as a diagnostic tool for caregiver burden.
The five subscales include: Time Dependency, Development, Physical Health, Emotional Health, and Social Relationships.
Each subscale contains 4-5 items which are statements of feelings.
Caregivers use a 5-point scale, anchored by "0" = "Never" and "4" = "Nearly Always", to show how often the statement describes his/her feelings.
Overall scores can range from 0 (minimum) to 96 (maximum), where a score near or above 36 indicates significant burden.
Higher scores indicate greater caregiver burden (i.e., worse outcome).
All subscales have a maximum score of 20, except Physical Health which has a maximum score of 16.
Subscale scores and item scores help identify the underlying cause of caregiver burden.
This measure will be completed electronically on an iPad using REDCap.
|
baseline to 12 weeks
|
Mean Change in Family Dermatology Life Quality Index
Time Frame: baseline to 12 weeks
|
The FDLQI is a 10-item questionnaire designed for adult family members of a patient with a skin disease.
It measures the impact of the patient's skin disease on the family member's quality of life.
The caregiver will answer each question using a 4-point scale: Not at all = 0, A Little = 1, Quite A Lot = 2, Very Much = 3.
The scores from each item are summed to create a severity burden score (i.e., minimum score = 0; maximum score = 30).
Higher scores indicate worse quality of life.
The scores represent degree of severity burden on quality of life: No effect = 0-1; Small effect = 2-6; Moderate effect = 7-12; Very large effect = 13-18; and Extremely large effect = 19-30.
This measure will be completed electronically on an iPad using REDCap.
|
baseline to 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Julie R Wolf, PhD, MPH, University of Rochester
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 20, 2019
Primary Completion (Actual)
August 1, 2021
Study Completion (Actual)
August 1, 2021
Study Registration Dates
First Submitted
August 22, 2018
First Submitted That Met QC Criteria
August 22, 2018
First Posted (Actual)
August 24, 2018
Study Record Updates
Last Update Posted (Actual)
October 31, 2022
Last Update Submitted That Met QC Criteria
October 27, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Skin Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Stress, Psychological
- Skin Diseases, Genetic
- Hypersensitivity
- Skin Diseases, Eczematous
- Dermatitis
- Eczema
- Dermatitis, Atopic
- Caregiver Burden
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Immunosuppressive Agents
- Immunologic Factors
- Calcineurin Inhibitors
- Tacrolimus
Other Study ID Numbers
- RSRB73062
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
Regeneron PharmaceuticalsSanofiRecruitingModerate-to-Severe Atopic Dermatitis | Atopic EczemaUnited States
-
AnaptysBio, Inc.RecruitingAtopic Dermatitis EczemaUnited States, Canada, Georgia, New Zealand
Clinical Trials on Crisaborole
-
PfizerCompletedAtopic DermatitisChina, Japan, Korea, Republic of
-
PfizerTerminated
-
Northwestern UniversityPfizerCompleted
-
PfizerCompletedAtopic DermatitisChina, United States, Turkey, Australia, Canada, Israel
-
PfizerCompletedAtopic DermatitisUnited States, Australia, Canada
-
PfizerCompleted
-
PfizerCompletedStasis DermatitisUnited States
-
PfizerCompleted
-
Innovaderm Research Inc.CompletedDermatitis, AtopicCanada
-
University of California, IrvinePfizerCompletedAtopic Dermatitis | Atopic Dermatitis EczemaUnited States